Logotipo do repositório

Efficacy and tolerability of 1.6% phenol-croton peeling vs. topical 5% imiquimod in the treatment of actinic cheilitis: a randomized controlled trial

dc.contributor.authorGarbers, Luiz Eduardo Fabrício De Melo
dc.contributor.authorMiola, Anna Carolina
dc.contributor.authorSouza, Vinicius de
dc.contributor.authorBrommonschenkel, Christina de Castro
dc.contributor.authorLima, Flavio de Oliveira
dc.contributor.authorMinicucci, Eliana Maria
dc.contributor.authorMiot, Helio Amante
dc.contributor.institutionUniversidade Estadual Paulista (UNESP)pt
dc.date.accessioned2026-08-17T17:14:24Z
dc.date.issued2024-11-21
dc.description.abstractBACKGROUND: Trials evaluating the effectiveness of topical treatments for actinic cheilitis (AC) are scarce. Despite no comparative data, phenol-croton peeling has been reported as effective in treating this condition. OBJECTIVE: To assess for the treatment of AC the efficacy and tolerability of a single session of 1.6% phenol-croton peeling vs. topical 5% imiquimod cream applied for 30 days for the treatment of AC. METHODS: An open, randomized controlled trial was conducted to compare the effectiveness and tolerability of 1.6% phenol-croton peeling vs. topical 5% imiquimod for the treatment of AC [protocol registered at ReBEC (Brazilian Registry of Clinical Trials) - RBR-1044sz68]. Thirty-six patients with biopsy-proven AC were allocated into two groups (1 : 1): the imiquimod group received 5% topical imiquimod three times a week for 30 days, and the croton group underwent one session of 1.6% phenol-croton peeling. The primary outcome was the clearance of AC after 56 days. Secondary outcomes included clinical and histological parameters, adverse effects and clinical results after 180 days. RESULTS: Complete clinical clearance of AC (defined as clearance of both leukoplakia and hyperkeratosis) at day 56 and day 180 occurred in 17 of 18 (94%) participants from the croton group but in none of the 18 participants in the imiquimod group (P < 0.01). Improvement in all clinical parameters was more prominent in the croton group (P ≤ 0.01). Complete histological normalization at day 56 occurred in 72% of the croton group and only 17% in the imiquimod group (P < 0.01). Histological parameters such as atypia (keratinocyte intraepithelial neoplasia score), solar elastosis and hyperkeratosis reduced in intensity only in the croton group (P < 0.05). Adverse effects were most intense on day 7 in the croton group and persisted until day 21 in the imiquimod group. The study was prematurely terminated at the interim analysis. CONCLUSIONS: A single session of 1.6% phenol-croton peeling produced clinically and histologically superior results with a shorter recovery period compared with imiquimod for treating AC.
dc.description.affiliationFaculdade de Medicina de Botucatu, UNESP Medical School, Botucatu, SP, Brazil
dc.description.affiliationUnespFaculdade de Medicina de Botucatu, UNESP Medical School, Botucatu, SP, Brazil
dc.identifierhttps://app.dimensions.ai/details/publication/pub.1182564358
dc.identifier.dimensionspub.1182564358
dc.identifier.doi10.1093/ced/llae520
dc.identifier.issn0307-6938
dc.identifier.issn1365-2230
dc.identifier.orcid0000-0001-8848-3040
dc.identifier.orcid0000-0002-4664-6929
dc.identifier.orcid0000-0002-2596-9294
dc.identifier.pmid39570668
dc.identifier.urihttps://hdl.handle.net/11449/329755
dc.publisherOxford University Press (OUP)
dc.relation.ispartofClinical and Experimental Dermatology; n. 4; v. 50; p. 826-835
dc.rights.accessRightsAcesso restritopt
dc.rights.sourceRightsclosed
dc.sourceDimensions
dc.titleEfficacy and tolerability of 1.6% phenol-croton peeling vs. topical 5% imiquimod in the treatment of actinic cheilitis: a randomized controlled trial
dc.typeArtigopt
dspace.entity.typePublication
relation.isOrgUnitOfPublicationa3cdb24b-db92-40d9-b3af-2eacecf9f2ba
relation.isOrgUnitOfPublication.latestForDiscoverya3cdb24b-db92-40d9-b3af-2eacecf9f2ba
unesp.campusUniversidade Estadual Paulista (UNESP), Faculdade de Medicina, Botucatupt

Arquivos